PT934061E - Isobutilgaba e seus derivados para o tratamento da dor - Google Patents

Isobutilgaba e seus derivados para o tratamento da dor

Info

Publication number
PT934061E
PT934061E PT97932617T PT97932617T PT934061E PT 934061 E PT934061 E PT 934061E PT 97932617 T PT97932617 T PT 97932617T PT 97932617 T PT97932617 T PT 97932617T PT 934061 E PT934061 E PT 934061E
Authority
PT
Portugal
Prior art keywords
pain
isobutilgaba
derivatives
treatment
gamma
Prior art date
Application number
PT97932617T
Other languages
English (en)
Inventor
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21809080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT934061(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PT934061E publication Critical patent/PT934061E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT97932617T 1996-07-24 1997-07-16 Isobutilgaba e seus derivados para o tratamento da dor PT934061E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2233796P 1996-07-24 1996-07-24

Publications (1)

Publication Number Publication Date
PT934061E true PT934061E (pt) 2003-10-31

Family

ID=21809080

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97932617T PT934061E (pt) 1996-07-24 1997-07-16 Isobutilgaba e seus derivados para o tratamento da dor

Country Status (23)

Country Link
US (2) US6001876A (pt)
EP (1) EP0934061B3 (pt)
JP (1) JP3693258B2 (pt)
KR (1) KR100491282B1 (pt)
CN (1) CN1094757C (pt)
AT (1) ATE241351T1 (pt)
AU (1) AU714980B2 (pt)
BR (1) BR9710536A (pt)
CA (1) CA2255652C (pt)
CU (1) CU22850A3 (pt)
DE (1) DE69722426T3 (pt)
DK (1) DK0934061T6 (pt)
ES (1) ES2200184T7 (pt)
HR (1) HRP970387A2 (pt)
HU (2) HU228426B1 (pt)
IL (1) IL126999A (pt)
NO (2) NO325822B1 (pt)
NZ (1) NZ332762A (pt)
PL (1) PL189872B1 (pt)
PT (1) PT934061E (pt)
SI (1) SI0934061T1 (pt)
WO (1) WO1998003167A1 (pt)
ZA (1) ZA976562B (pt)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
DE69832712T2 (de) * 1997-09-08 2006-06-22 Warner-Lambert Company Llc Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
CN1303991C (zh) * 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
PT1093366E (pt) * 1998-07-09 2005-02-28 Warner Lambert Co Composicao farmaceutica que contem analogos de gaba e um agente antiviral para o tratamento de herpes zoster
NZ508491A (en) * 1998-07-09 2003-09-26 Warner Lambert Co Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
AU766708B2 (en) * 1998-07-09 2003-10-23 Warner-Lambert Company The treatment of renal colic with GABA analogs
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
DE60041256D1 (de) * 1999-06-10 2009-02-12 Warner Lambert Co Mono-substituierte 3-propyl-gamma-aminobuttersäure
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
ME00921B (me) * 2000-01-27 2012-06-20 Warner Lambert Co Asimetrična sinteza pregabalina
US6687187B2 (en) * 2000-08-11 2004-02-03 Phonak Ag Method for directional location and locating system
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1404324B2 (en) 2001-06-11 2011-04-06 XenoPort, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE317280T1 (de) * 2001-09-03 2006-02-15 Newron Pharm Spa Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003297927A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
EP1572184A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company Gabapentin analogues for fibromyalgia and other related disorders
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
WO2004054565A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CA2538802C (en) * 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
PT1677767E (pt) 2003-10-14 2011-10-13 Xenoport Inc Forma cristalina de análogo de ácido gama-aminobutírico
WO2005053667A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
CA2559086A1 (en) * 2004-03-12 2005-09-22 Warner-Lambert Company Llc C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
JP2007530657A (ja) * 2004-04-01 2007-11-01 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐキラル性ホスホランの調製および不斉合成でのその使用
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
WO2006000904A2 (en) 2004-06-21 2006-01-05 Warner-Lambert Company Llc Preparation of pregabalin and related compounds
MX2007002269A (es) * 2004-08-27 2007-06-15 Sanol Arznei Schwarz Gmbh Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
BRPI0517227B8 (pt) * 2004-11-04 2021-05-25 Xenoport Inc comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
KR100893312B1 (ko) * 2005-05-10 2009-04-15 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린 및 이의 염의 제조 방법
CA2604624A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
CA2608010A1 (en) * 2005-05-20 2006-11-23 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
CA2619473C (en) * 2005-09-19 2012-04-17 Teva Pharmaceutical Industries Ltd. An asymmetric synthesis of (s)-(+)-3-(aminomethyl)-5-methylhexanoic acid
US7462738B2 (en) * 2006-05-24 2008-12-09 Teva Pharmaceutical Industries Ltd. Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
EP2462990B2 (en) 2006-06-15 2018-04-18 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam with synergistic anticonvulsant effect
BRPI0803092A2 (pt) * 2007-03-22 2011-08-30 Teva Pharma sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina
KR20090101462A (ko) * 2007-10-03 2009-09-28 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010070593A2 (en) 2008-12-19 2010-06-24 Pfizer Ireland Pharmaceuticals Malonate esters
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
NZ596492A (en) 2009-05-15 2013-08-30 Redx Pharma Ltd Redox drug derivatives
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
WO2012025861A1 (en) 2010-08-23 2012-03-01 Pfizer Manufacturing Ireland Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
IN2014DN06965A (pt) 2012-01-30 2015-04-10 Ranbaxy Lab Ltd
IN2014DN06966A (pt) 2012-01-30 2015-04-10 Ranbaxy Lab Ltd
CN102966602B (zh) * 2012-12-14 2015-08-05 江苏海鸥冷却塔股份有限公司 一种冷却塔节能导流风筒
ES2961655T3 (es) 2013-01-18 2024-03-13 Kemphys Ltd Medicamento para tratamiento de enfermedad neuropática
DK2978748T3 (en) 2013-03-27 2017-07-24 Pfizer Ireland Pharmaceuticals Process and intermediates for the preparation of pregabalin
JP2018520112A (ja) 2015-05-26 2018-07-26 オディディ，イサ 制御持続放出プレガバリン
GB201617380D0 (en) * 2016-10-13 2016-11-30 St George's Hospital Medical School Treatment for Osteoarthritis
KR102039344B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
KR102039345B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
GB201703123D0 (en) * 2017-02-27 2017-04-12 St George's Hospital Medical School Biomarkers
WO2019219000A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
CN108926573A (zh) * 2018-07-03 2018-12-04 泓博元生命科技（深圳）有限公司 一种可降低尿酸指数的nadh组合物及其制备方法及应用
KR20200056719A (ko) 2018-11-15 2020-05-25 단국대학교 천안캠퍼스 산학협력단 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물
TW202139981A (zh) 2020-01-22 2021-11-01 美商西羅斯醫療公司 降低nmda拮抗劑之副作用
WO2021191108A1 (en) 2020-03-23 2021-09-30 Plus Vitech, S.L. Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid
WO2022038131A1 (en) 2020-08-19 2022-02-24 Plus Vitech, S.L. Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage
MX2023008648A (es) 2021-01-22 2023-10-06 Egyt Gyogyszervegyeszeti Gyar Formulacion topica que contiene compuestos fosfolipidicos modificados.
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
WO2022234110A1 (en) 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy
WO2022243430A1 (en) 2021-05-20 2022-11-24 Plus Vitech, S.L. Treatment of acne
WO2022253748A1 (en) 2021-06-03 2022-12-08 Plus Vitech, S.L. Combinations for the treatment of hpv

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
JPS4940460Y2 (pt) 1971-05-19 1974-11-06
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4123438A (en) 1975-03-05 1978-10-31 Stamicarbon, B.V. Process for preparing 2-pyrrolidones
NZ194348A (en) 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
US4322440A (en) 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
FI832935A7 (fi) 1982-08-20 1984-02-21 Midit Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar
US4479005A (en) 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
EP0133795B1 (en) 1983-08-01 1989-01-18 THE McLEAN HOSPITAL CORPORATION Gaba esters and gaba analogue esters
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
NO166131C (no) 1985-06-20 1991-06-05 Daiichi Seiyaku Co Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
JP2535001B2 (ja) 1987-01-13 1996-09-18 ダイセル化学工業株式会社 Ｎ−アルキル化アミノ酸エステルの製法
JPH07116064B2 (ja) 1987-07-21 1995-12-13 三菱化学株式会社 分離剤
US4908210A (en) 1988-10-28 1990-03-13 Eastman Kodak Company Lactylic salt tablet formulations and tablets
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
GB8921304D0 (en) 1989-09-20 1989-11-08 Wyeth John & Brother Ltd New method of treatment and heterocyclic compounds used therein
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
WO1992014443A1 (en) 1991-02-20 1992-09-03 Warner-Lambert Company Microsphere-in-oil emulsion
DK204791D0 (da) 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
WO1993023383A1 (en) * 1992-05-20 1993-11-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
GB9308430D0 (en) 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
HU223841B1 (hu) 1994-07-27 2005-02-28 Warner-Lambert Company Gabepentin alkalmazása szorongás és pánik kezelésére alkalmazható gyógyszerkészítmények előállítására
US5792796A (en) 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
WO1996021661A1 (en) 1995-01-12 1996-07-18 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
JPH11501016A (ja) 1995-02-28 1999-01-26 ハー・ルンドベック・アクチェゼルスカベット ４−アミノテトラヒドロベンズイソオキサゾール又は−イソチアゾール化合物
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
US5616793A (en) 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
HUP9901074A3 (en) 1996-02-07 2001-08-28 Warner Lambert Co Tetrahydropyrane and tetrahydrothiopyrane aminoacids and pharmaceutical compositions containing them
EP0888285B1 (en) 1996-03-14 2001-12-12 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
DK0888285T3 (da) 1996-03-14 2002-04-08 Warner Lambert Co Nye broforbundne cycliske aminosyrer som farmaceutiske midler
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
AU714542B2 (en) 1996-06-26 2000-01-06 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999008667A2 (en) 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
DE69832712T2 (de) 1997-09-08 2006-06-22 Warner-Lambert Company Llc Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
PL348305A1 (en) 1997-12-16 2002-05-20 Warner Lambert Co Novel amines as pharmaceutical agents
CN1303991C (zh) 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
KR100669280B1 (ko) 1998-05-15 2007-01-17 워너-램버트 캄파니 엘엘씨 감마-아미노부티르산 유도체 포함 고상 조성물 및 그의제조 방법
US20030045500A1 (en) 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
PL345340A1 (en) 1998-07-09 2001-12-17 Warner Lambert Co Compositions comprising gaba analogs and caffeine
US6306910B1 (en) 1998-07-09 2001-10-23 Warner-Lambert Company Use of Gaba-analogues for treating insomnia
KR100697734B1 (ko) 1998-10-16 2007-03-22 워너-램버트 캄파니 엘엘씨 조증 및 양극성 장애 치료용 제약 조성물
JP2002538221A (ja) 1999-03-10 2002-11-12 ワーナー−ランバート・カンパニー 抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
US6992109B1 (en) 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
TR200102850T2 (tr) 1999-04-09 2002-03-21 Warner-Lambert Company Depresyonun iyileçtirilmesi i‡in gaba analoglarì ve trisiklik bileçiklerin kombinasyonlarì
DK1187832T3 (da) 1999-06-02 2003-03-10 Warner Lambert Co Aminoheterocycler, som er anvendelige som farmaceutiske midler
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
AU5753900A (en) 1999-07-02 2001-01-22 Warner-Lambert Company A synergistic combination: gabapentin and pregabalin
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
WO2001020336A2 (en) 1999-09-16 2001-03-22 Warner-Lambert Company SCREENING FOR α2δ-1 SUBUNIT BINDING LIGANDS
AP2002002501A0 (en) 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
ME00921B (me) 2000-01-27 2012-06-20 Warner Lambert Co Asimetrična sinteza pregabalina
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP2003533223A (ja) 2000-05-16 2003-11-11 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー α２δ２カルシウムチャネルサブユニットの発現細胞株
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
CA2356829A1 (en) 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
WO2002043762A2 (en) 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
CA2430309A1 (en) 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
ES2236134T3 (es) 2000-12-13 2005-07-16 Warner-Lambert Company Llc Ligandos bisfosfolanos p-quirales y sus complejos con metales de transicion.
US20040002543A1 (en) 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
ATE297902T1 (de) 2001-02-28 2005-07-15 Pfizer Prod Inc Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
MXPA02001147A (es) 2001-03-19 2004-04-21 Warner Lambert Co Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica.
US7022678B2 (en) 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
SI1373259T1 (en) 2001-03-30 2005-04-30 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
SK12822003A3 (sk) 2001-04-19 2004-04-06 Warner - Lambert Company Llc Fúzne bicyklické alebo tricyklické aminokyseliny
NZ529173A (en) 2001-05-25 2005-07-29 Warner Lambert Co Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol
US20030045449A1 (en) 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10203122A1 (de) 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
CN1625393A (zh) 2002-01-31 2005-06-08 沃纳-兰伯特公司 治疗耳鸣的α2δ配体
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US20030225149A1 (en) 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
BR0312240A (pt) 2002-06-27 2005-04-12 Warner Lambert Co Método de tratamento do distúrbio por déficit de atenção com hiperatividade
DK1521733T3 (da) 2002-07-08 2014-10-13 Pfizer Prod Inc Modulatorer af glucocorticoid receptoren
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040092522A1 (en) 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
MXPA05005585A (es) 2002-12-06 2005-07-27 Warner Lambert Co Benzoxazin-3-onas y derivados de las mismas como agentes terapeuticos.
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2004054565A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN1791430A (zh) 2003-05-16 2006-06-21 辉瑞产品公司 非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合
EP1644360A1 (en) 2003-06-05 2006-04-12 Warner-Lambert Company LLC 3-substituted indoles and derivatives thereof as therapeutic agents
WO2005002585A1 (en) 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
MXPA06002550A (es) 2003-09-03 2006-06-20 Pfizer Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4.
RU2006107534A (ru) 2003-09-12 2007-09-20 Уорнер-Ламберт Компани Ллс (Us) Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005030703A1 (en) 2003-09-25 2005-04-07 Warner-Lambert Company Llc PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1543831A1 (en) 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
JP2007537151A (ja) 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
CA2559086A1 (en) 2004-03-12 2005-09-22 Warner-Lambert Company Llc C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
BRPI0509377A (pt) 2004-03-29 2007-09-11 Pfizer compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1
JP2007530657A (ja) 2004-04-01 2007-11-01 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐキラル性ホスホランの調製および不斉合成でのその使用
EP1742950B1 (en) 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
UA82292C2 (uk) 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
WO2005102389A2 (en) 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
CA2563707A1 (en) 2004-04-20 2005-11-03 Pfizer Inc. Method of treating neuropathic pain using a crth2 receptor antagonsit
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
CA2564994A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
BRPI0512046A (pt) 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
WO2006000904A2 (en) 2004-06-21 2006-01-05 Warner-Lambert Company Llc Preparation of pregabalin and related compounds
AU2005258911A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
US20060003344A1 (en) 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
WO2006008640A1 (en) 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
GB0419849D0 (en) 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
ES2318556T3 (es) 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
CN101087771A (zh) 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
AU2005308523B2 (en) 2004-11-29 2010-01-07 Warner-Lambert Company Llc Therapeutic pyrazolo[3,4-b] pyridines and indazoles
EA012615B1 (ru) 2005-02-22 2009-10-30 Пфайзер Инк. Производные оксииндола в качестве агонистов 5-htрецептора
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
WO2006095263A1 (en) 2005-03-10 2006-09-14 Pfizer Japan Inc. Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
EP1861359B1 (en) 2005-03-17 2012-11-14 Pfizer Inc. N-(n-sulfonylaminomethyl)cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2006111856A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
CN101166524B (zh) 2005-04-28 2010-12-22 辉瑞有限公司 氨基酸衍生物
CA2608010A1 (en) 2005-05-20 2006-11-23 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
EP1893583B1 (en) 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
CN101304974A (zh) 2005-11-08 2008-11-12 辉瑞有限公司 吡唑衍生物和它们的医药用途
WO2007063391A2 (en) 2005-12-02 2007-06-07 Pfizer Limited Spirocyclic quinazoline derivatives as pde7 inhibitors
CA2530904C (en) 2005-12-20 2013-10-08 John Marino Pharmaceutical agents for the treatment of pain associated with spinal cord injury
CN101420947A (zh) 2006-03-06 2009-04-29 辉瑞产品公司 用于非恢复性睡眠的α-2-δ配体
GB0700786D0 (en) 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
ES2368286T3 (es) 2007-02-02 2011-11-16 Pfizer Products Inc. Compuestos tricíclicos y su uso como moduladores de los receptores de glucocorticoides.
WO2008132589A1 (en) 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin

Also Published As

Publication number Publication date
CN1223574A (zh) 1999-07-21
JP2000515149A (ja) 2000-11-14
NO2008018I1 (no) 2008-12-15
ES2200184T3 (es) 2004-03-01
HRP970387A2 (en) 1998-10-31
EP0934061A1 (en) 1999-08-11
WO1998003167A1 (en) 1998-01-29
KR100491282B1 (ko) 2005-05-24
IL126999A0 (en) 1999-09-22
DK0934061T6 (en) 2015-01-26
ZA976562B (en) 1998-02-03
SI0934061T1 (en) 2003-10-31
BR9710536A (pt) 1999-08-17
EP0934061B3 (en) 2015-01-21
ES2200184T9 (es) 2015-03-20
DE69722426T3 (de) 2015-05-07
HU228426B1 (hu) 2013-03-28
USRE41920E1 (en) 2010-11-09
HK1021134A1 (en) 2000-06-02
HUP9904361A2 (hu) 2000-05-28
NZ332762A (en) 2000-09-29
NO325822B1 (no) 2008-07-21
CA2255652A1 (en) 1998-01-29
AU714980B2 (en) 2000-01-13
US6001876A (en) 1999-12-14
NO990279D0 (no) 1999-01-22
AU3602497A (en) 1998-02-10
KR20000068015A (ko) 2000-11-25
EP0934061B1 (en) 2003-05-28
IL126999A (en) 2002-03-10
DE69722426D1 (de) 2003-07-03
NO2008018I2 (no) 2010-06-28
PL189872B1 (pl) 2005-10-31
JP3693258B2 (ja) 2005-09-07
ES2200184T7 (es) 2015-02-10
NO990279L (no) 1999-01-22
CA2255652C (en) 2004-07-13
ATE241351T1 (de) 2003-06-15
DK0934061T3 (da) 2003-09-22
CN1094757C (zh) 2002-11-27
DE69722426T2 (de) 2004-04-08
HUP9904361A3 (en) 2000-11-28
CU22850A3 (es) 2003-04-28
HUS1300046I1 (hu) 2016-08-29
PL331325A1 (en) 1999-07-05

Similar Documents

Publication Publication Date Title
PT934061E (pt) Isobutilgaba e seus derivados para o tratamento da dor
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
BR9911887A (pt) Método para o tratamento da insÈnia
DE59608698D1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
DK0855916T3 (da) Farmaceutisk præparat indeholdende en Activin-stimulator
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
FI973023L (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
BR9506748A (pt) Compostos preparação farmacêutica utilização de um composto e processos para o tratamento de um indivíduo sofrendo de dor e para a preparação de um composto
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
ATE211650T1 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
BR9708037A (pt) Método para o tratamento de abuso de substância
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO984190L (no) FremgangsmÕte for behandling av insomnia
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
BG100116A (bg) Инвазивен метод за лечение на енкопреза и енурезис ноктурна в комбинация или поотделно